- AuthorisedTherapeutic use (Phase IV)
Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
This study looks at how different doses of nivolumab, a cancer medicine, work in people with melanoma or kidney cancer. It wants to find the best dose to keep the medicine effective while perhaps using less. This could make treatment easier and more affordable.
For: Melanoma, Renal cell carcinomaNetherlands - Active not recruitingPHASE3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
This study looks at a new immune-boosting medicine called Nivolumab for people who have had surgery for bladder or kidney drainage system cancer. It compares Nivolumab to a dummy drug to see if it's safe and helps stop the cancer from coming back.
For: Various Advanced CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Study of Novel Treatment Combinations in Patients With Lung Cancer
This study looks at new drug combinations to treat lung cancer. It has three parts: for cancer that has spread, cancer that has grown despite previous treatment, and earlier-stage cancer that can be removed by surgery.
For: Lung Cancer · Advanced or Metastatic Non-Small-Cell Lung Cancer · Resectable Non-Small-Cell Lung CancerUnited States · Brazil · Hong Kong - RecruitingPHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
This study is for adults with a certain type of lung cancer (Stage II-IIIB non-small cell lung cancer) that has a specific genetic change (HER2 mutation) and has been fully removed by surgery. It compares a new daily tablet called zongertinib with standard treatments to see if it can stop the cancer from coming back.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2, PHASE3
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
This study is looking at a new combination of medicines, relatlimab and nivolumab, for advanced melanoma. It aims to see if this combination works better than nivolumab alone for melanoma that has spread or can't be removed by surgery.
For: MelanomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This study is testing a new drug, BT5528, for advanced cancers like ovarian, lung, and breast cancer. We want to find a safe dose, understand side effects, and see how well it works, sometimes given with another drug called nivolumab.
For: Advanced Solid Tumor Historically Known for High EphA2 Expression · Urothelial Cancer · Ovarian CancerUnited States · Belgium · South Korea - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
For: Only patients with oncologic locally advanced or metastatic tumour (lung cancer · renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination) · head and neck cancerFrance - Active not recruitingPHASE1
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
This study is testing a new treatment called RP3, alone and with another drug called Nivolumab, for advanced cancers. It aims to find out if RP3 is safe and how much to give for future studies.
For: Advanced Solid TumorUnited States · France · Greece - RecruitingPHASE2, PHASE3
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
This study compares two drug combinations for advanced uveal melanoma. It looks at RP2 with nivolumab versus nivolumab with ipilimumab, for patients who haven't had these immune-boosting treatments before, to see which works better and is safer.
For: Metastatic Uveal MelanomaUnited States · Australia · United Kingdom - Active not recruitingPHASE1
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
This study is testing a new treatment called RP2, alone and with nivolumab, for adults with advanced cancers. It aims to find the safest dose and see how well it works. RP2 is a modified virus designed to fight cancer.
For: CancerSpain · United Kingdom - RecruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
This study is looking at a new treatment for a type of bladder cancer called muscle-invasive urothelial carcinoma (MIUC). It combines an experimental medicine, autogene cevumeran, with an existing drug, nivolumab, to see if this combination works better and is safe compared to nivolumab alone.
For: Muscle-invasive Urothelial CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
This study looks at treating muscle-invasive bladder cancer. It compares standard chemotherapy with chemotherapy plus a new immunotherapy drug called nivolumab, given before and after surgery. The aim is to see if adding nivolumab helps more people.
For: Urinary Bladder Neoplasms · Muscle-Invasive Bladder CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
This study is looking at new ways to treat neuroblastoma in children, a type of cancer. It combines standard treatment with new medicines (Nivolumab and Dinutuximab Beta) to see if they are safe and helpful. The goal is to find better treatments for children whose cancer has come back or is hard to treat.
For: NeuroblastomaUnited States · United Kingdom - RecruitingPHASE2
CD8 PET Imaging in Metastatic Solid Tumours
This study looks at a new type of specialised scan for people with advanced cancer. It uses a small amount of a special substance called 89Zr-Df-crefmirlimab to create detailed pictures. This helps doctors see how well a new cancer treatment, called PD-1 antibody therapy, is working.
For: Locally Advanced Solid TumorNetherlands · Spain · United Kingdom - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
This study is looking at new combinations of medicines for advanced lung or breast cancer. We want to see if they are safe, how much medicine gets into the body, and if they show early signs of working. It's for adults with certain types of advanced cancer.
For: Lung Cancer · Breast CancerUnited States · Australia · Canada - RecruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
For: Renal Cell Carcinoma (RCC) · Metastatic Castration-Resistant Prostate Cancer (mCRPC) · Urothelial Carcinoma (UC)United States · Australia · Austria - AuthorisedTherapeutic exploratory (Phase II)
IMMUNOPEC: Combination of neo-adjuvant Checkpoint Inhibition and Dendritic Cell Therapy (MesoPher) with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in patients with Peritoneal Mesothelioma
This study is looking at a new combination treatment for peritoneal mesothelioma. It combines existing cancer drugs with a special vaccine, followed by surgery and chemotherapy. The main goal is to see how long patients live without their cancer growing.
For: Peritoneal MesotheliomaNetherlands - RecruitingPHASE1, PHASE2
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
This study looks at a new drug, mRNA-4359, by itself and with other cancer drugs. It aims to see if it's safe and what side effects it might have in people with advanced solid tumours, which are cancers that have spread.
For: Advanced Solid TumorsUnited States · Australia · Italy - Active not recruitingPHASE3
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
This study looks at a medicine called nivolumab for liver cancer. It's for people who've had surgery or other treatment to remove their cancer, but are at high risk of it coming back. We want to see if nivolumab can stop the cancer from returning.
For: Hepatocellular Carcinoma · Liver CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is testing new combinations of medicines (Nivolumab with Cabozantinib) against a standard treatment (Sunitinib) for kidney cancer that has spread. We want to see if the new combination is safer and works better for people who haven't had treatment before.
For: Renal Cell CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE2
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
This study looks at a new combination of immunotherapy (Nivolumab and Relatlimab) for advanced bowel cancer that has spread. It focuses on patients whose cancer stopped responding to previous treatments, hoping to find new options.
For: Metastatic Colorectal CancerUnited Kingdom - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It combines three medicines to see if they work better together than two, aiming to help people live longer and keep their cancer from growing.
For: Renal Cell CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
This study is looking into a new treatment called nivolumab for people with certain types of thymus gland cancer (Type B3 Thymoma or Thymic Carcinoma) that has come back or spread, and has already been treated with chemotherapy.
For: Thymoma Type B3 · Thymic CarcinomaBelgium · France · Netherlands - Active not recruitingPHASE3
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
This study looks at a new drug, bemarituzumab, in combination with standard chemotherapy and nivolumab for advanced stomach or food pipe cancer. It aims to see if this new combination is safe and works better than current treatments, helping people with specific types of cancer live longer.
For: Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
This study is looking at whether a drug called nivolumab can help prevent melanoma skin cancer from coming back in people who have had surgery to remove it. It compares nivolumab to a dummy treatment (placebo) in adults and children at high risk of their cancer returning.
For: MelanomaUnited States · Australia · Austria - Active not recruitingPHASE3
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This study is for women with advanced ovarian cancer who've had their first treatment. It's testing if two medications, rucaparib and nivolumab, given after initial treatment, can help prevent the cancer from returning or growing. It compares these drugs to dummy treatments.
For: Epithelial Ovarian Cancer · Primary Peritoneal · Fallopian Tube CancerUnited States · Australia · Belgium - RecruitingPHASE3
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
This study looks at a new treatment called VO with nivolumab for advanced melanoma that has grown despite earlier treatments. It compares this combination to standard treatments chosen by your doctor for people aged 12 and over.
For: Advanced MelanomaUnited States · France · Germany - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
For: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal CancerUnited States · Australia · Austria - RecruitingPHASE2, PHASE3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
This study looks at new drug Pumitamig with chemotherapy, or Nivolumab with chemotherapy, for advanced stomach, gastroesophageal junction, or oesophageal cancer. It aims to see how safe and effective these combinations are for people who haven't had treatment for their advanced cancer.
For: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This study is testing a new combination of medicines with chemotherapy for some upper gut cancers that have spread and can't be removed by surgery. It aims to see if the new combination works better than current treatments.
For: Advanced Upper Gastrointestinal Tract AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
This study looks at the long-term effects of a medicine called belzutifan for people with advanced cancers or cancers linked to Von Hippel-Lindau disease. It's for those already taking belzutifan in other trials. The aim is to see how long people live after starting this treatment.
For: Von Hippel-Lindau Disease · Carcinoma, Renal CellUnited States · Belgium · Canada - Active not recruitingPHASE2
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
This study looks at a new treatment called RP1, by itself and with another drug called nivolumab. It's for people with certain advanced cancers like lung cancer, some skin cancers, and specific solid tumours that haven't responded well to previous treatments.
For: Non-Small Cell Lung Cancer (NSCLC) · Microsatellite Instability-High (MSI-H) · Non-melanoma Skin Cancer (NMSC)United States · France · Germany - Active not recruitingPHASE1
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
This study tests new ways to treat advanced pancreatic cancer. It combines a targeted drug (anetumab ravtansine) with immune-boosting medicines (nivolumab, ipilimumab) and standard chemotherapy (gemcitabine) to see if these combinations are safe and effective.
For: Pancreatic Adenocarcinoma · Stage II Pancreatic Cancer AJCC v8 · Stage III Pancreatic Cancer AJCC v8United States · Canada - RecruitingPHASE2
Using ctDNA to Determine Therapies for Lung Cancer
This study looks at a special blood test for lung cancer. If tiny bits of cancer DNA are found after surgery, researchers want to see if extra treatment can stop the cancer from coming back. It aims to help doctors decide who most needs further treatment.
For: Non Small Cell Lung Cancer · Complete Surgical Resection · Circulating Tumor DNACanada - RecruitingPHASE2
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
This study looks at combining nivolumab, an immunotherapy drug, with chemotherapy and then radiation for young people with nasopharyngeal cancer. Researchers want to see if this new treatment can fight the cancer effectively, understand its side effects, and potentially reduce radiation for children.
For: Stage II Nasopharyngeal Carcinoma AJCC v8 · Stage III Nasopharyngeal Carcinoma AJCC v8 · Stage IV Nasopharyngeal Carcinoma AJCC v8United States · Canada · New Zealand - Active not recruitingPHASE2
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
This study looks at treating advanced soft tissue sarcoma with a combination of two immunotherapy drugs (ipilimumab and nivolumab), alone or with an additional drug called cabozantinib, to see which works best.
For: Locally Advanced Extraskeletal Myxoid Chondrosarcoma · Locally Advanced Leiomyosarcoma · Locally Advanced LiposarcomaUnited States · Canada - Active not recruitingPHASE1, PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
This study is testing a new cell therapy called gavo-cel for advanced cancers like mesothelioma and ovarian cancer. It explores how well gavo-cel works, both alone and with other cancer drugs, in people whose tumours produce a specific protein called mesothelin.
For: Mesothelioma · Mesothelioma, Malignant · Mesothelioma; PleuraUnited States · Canada - Active not recruitingPHASE3
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
This study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) when used with chemotherapy for newly diagnosed, advanced Hodgkin lymphoma. It aims to see which combination works best at shrinking the cancer and keeping it away.
For: Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Ann Arbor Stage III Mixed Cellularity Classic Hodgkin LymphomaUnited States · Canada · Puerto Rico - RecruitingPHASE2
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
This study looks at adding a new drug, relatlimab, to current treatments for nasopharyngeal cancer that has come back or spread. The aim is to see if this addition can help keep the cancer from growing or spreading for longer.
For: Metastatic Nasopharyngeal Carcinoma · Recurrent Nasopharyngeal Carcinoma · Stage IV Nasopharyngeal Carcinoma AJCC v8United States · Australia · Canada - Active not recruitingPHASE3
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck
This study looks at adding a new drug, nivolumab, to standard treatment for head and neck cancer after surgery. Researchers want to see if this combination improves health and prevents the cancer from coming back, without causing more problems.
For: Squamous Cell Carcinoma of Head and NeckFrance - Active not recruitingPHASE1, PHASE2
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
This study is looking at a new drug, BMS-986449, by itself and with another drug, nivolumab, for people with advanced cancers. Researchers want to see if these treatments are safe and effective. It's for patients whose cancer hasn't responded to usual treatments.
For: Advanced Solid TumorsUnited States · Belgium · France - RecruitingPHASE1
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
This study is looking at a new way to treat advanced liver cancer that can't be removed with surgery. It combines two existing cancer drugs, ipilimumab and nivolumab. Doctors want to find the safest and most effective dose when ipilimumab is given directly into the liver and nivolumab is given into the bloodstream.
For: Hepatocellular CarcinomaFrance - Active not recruitingPHASE1, PHASE2
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
This study is testing a new drug, BT7480, alone and with an existing drug, nivolumab, for advanced cancers that have a specific marker called Nectin-4. We want to find the safest dose, understand side effects, and see how well it works.
For: Advanced Solid TumorUnited States · United Kingdom - RecruitingPHASE2
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
This study looks at new treatments for advanced liver cancer that hasn't responded to initial therapy. It combines a new medicine, visugromab, with existing treatments (nivolumab and lenvatinib) to see if this mix is more effective and safe than lenvatinib alone.
For: Unresectable or Metastatic Hepatocellular Carcinoma · Child-Pugh A Hepatocellular Carcinoma · Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 CompoundGermany · Italy - RecruitingPHASE2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
This study is for people with advanced lung cancer that has spread. It tests new treatments using a drug called Visugromab, combined with Nivolumab and sometimes Docetaxel, to see if they can work better than existing options.
For: Metastatic Non-Squamous Non-Small Cell Lung Cancer · Adult Solid TumorUnited States · Germany · Italy - Active not recruitingPHASE3
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
This study is for people with advanced kidney cancer (non-clear cell type) that hasn't spread too widely. It compares a new combination of drugs (XL092 + nivolumab) with a standard treatment (sunitinib) to see which works better. Participants haven't had prior cancer medicine for their advanced kidney cancer.
For: Non-Clear Cell Renal Cell CarcinomaUnited States · Argentina · Australia - RecruitingPHASE4
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
This study looks at how well a treatment combining two drugs, nivolumab and cabozantinib, works for older patients (70 and over) with advanced kidney cancer. It aims to see how patients respond to this treatment in real-life use.
For: Kidney Cancer · Renal Cell CancerFrance